Clinical Trials and Drug Development in Neurodegeneration

Clinical Trials and Drug Development in Neurodegeneration focus on advancing innovative therapies to combat progressive neurological disorders such as Alzheimer’s, Parkinson’s, and Huntington’s disease. Cutting-edge clinical research involves rigorous phases to evaluate the safety, efficacy, and tolerability of novel neuroprotective agents and disease-modifying drugs. Leveraging biomarkers, genetic profiling, and advanced imaging technologies accelerates patient stratification and targeted treatment approaches. Ongoing drug development emphasizes slowing neurodegeneration, improving cognitive function, and enhancing quality of life. This dynamic field integrates translational neuroscience and precision medicine, aiming to transform therapeutic strategies and address unmet clinical needs in neurodegenerative disease management worldwide.

    Related Conference of Clinical Trials and Drug Development in Neurodegeneration

    September 14-15, 2026

    18th International Conference on Addiction & Psychiatry

    Barcelona, Spain
    September 14-15, 2026

    20th International Conference on Mental Health & Psychiatry

    Barcelona, Spain
    September 23-24, 2026

    6th Annual Congress on Mental Health

    Amsterdam, Netherlands
    October 19-20, 2026

    6thAnnual Congress on Mental Health & Psychiatry

    Paris, France

    Clinical Trials and Drug Development in Neurodegeneration Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in